Kymera Therapeutics (KYMR) Accounts Payables: 2019-2025
Historic Accounts Payables for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to $5.5 million.
- Kymera Therapeutics' Accounts Payables fell 15.21% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 15.21%. This contributed to the annual value of $6.0 million for FY2024, which is 15.35% down from last year.
- Kymera Therapeutics' Accounts Payables amounted to $5.5 million in Q3 2025, which was down 4.76% from $5.8 million recorded in Q2 2025.
- Kymera Therapeutics' 5-year Accounts Payables high stood at $10.3 million for Q1 2025, and its period low was $2.4 million during Q2 2022.
- Its 3-year average for Accounts Payables is $6.3 million, with a median of $6.5 million in 2023.
- In the last 5 years, Kymera Therapeutics' Accounts Payables crashed by 70.97% in 2022 and then surged by 152.55% in 2023.
- Quarterly analysis of 5 years shows Kymera Therapeutics' Accounts Payables stood at $4.0 million in 2021, then increased by 8.24% to $4.3 million in 2022, then spiked by 63.21% to $7.1 million in 2023, then fell by 15.35% to $6.0 million in 2024, then declined by 15.21% to $5.5 million in 2025.
- Its Accounts Payables stands at $5.5 million for Q3 2025, versus $5.8 million for Q2 2025 and $10.3 million for Q1 2025.